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Abstract
Aim: The amyloid precursor protein (APP) is endoproteolytically processed to generate either the neurotoxic beta-
amyloid peptide (Aβ) or the secreted ectodomain APP alpha (sAPPα). While neurotrophic properties of sAPPα were
suggested in several studies, it is still unclear if and how sAPPα counteracts pathogenic effects of Aβ. Direct comparisons
with sAPPβ, produced in the Aβ-generating pathway, are missing in order to determine the role of sAPPα’s carbonyl-
terminal end in its possible neuroprotective activity.
Methods: Mouse neuronal primary cultures and hippocampal slices were treated with oligomeric Aβ42. The effects on
tau phosphorylation and dendritic spine densities were assessed by western blot and confocal imaging, respectively.
Co-administration of either sAPPα or sAPPβ was used to determine activity on Aβ-induced toxicity.
Results/discussion: We found that oligomeric Aβ strongly increased AT8 and AT180 phosphorylation of tau and
caused a loss of dendritic spines. SAPPα completely abolished Aβ effects whereas sAPPβ had no such rescue activity.
Interestingly, sAPPα or sAPPβ alone neither affected tau phosphorylation nor dendritic spine numbers. Together, our
data suggest that sAPPα specifically protects neurons against Aβ-dependent toxicity supporting the strategy of
activating α-secretase-dependent endoproteolytic APP processing to increase sAPPα shedding from the neuronal
plasma membrane as a therapeutic intervention for the protection of dendritic spines and phospho-tau-dependent
toxicity in Alzheimer’s disease.
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Main text
The depositions of Aβ and hyperphosphorylated tau are the
major hallmarks of Alzheimer’s disease (AD). Aβ is pro-
duced by the amyloidogenic processing of APP. In this
pathway, APP is cleaved by β-secretase (BACE-1) generat-
ing soluble APPβ (sAPPβ) and the membrane-bound frag-
ment β-CTF. Further processing of β-CTF by γ-secretase
produces the APP intracellular domain (AICD) and Aβ
forms of various lengths. In the non-amyloidogenic path-
way, Aβ generation is precluded by α-secretase, i.e. the
metalloproteases ADAM10 and ADAM17, which cleave
within the Aβ sequence generating sAPPα and α-CTF. Sub-
sequent γ-secretase cleavage releases AICD and the P3
fragment (reviewed in [1]).
Most AD-related studies focus on the detrimental ef-
fect of Aβ and therapeutic interventions aim in reducing
Aβ levels. However, sAPP, especially sAPPα, is thought
to have neurotrophic and neuroprotective properties [2]
and its levels are strongly reduced in AD patients with
one of two copies of APOE4, the main risk factor for
AD. Interestingly, the levels of sAPPβ were not different
in AD patients compared to controls [3]. In contrast to
sAPPα, sAPPβ is not or much less potent in neuro-
trophic support [2]. In several studies on the beneficial
or detrimental effects of sAPPα or sAPPβ, the direct
comparison of both is lacking. Here we aim to explore
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the neuroprotective properties of sAPPα on Aβ-induced
neuronal dysfunction in direct comparison to sAPPβ.
Oligomeric Aβ induces hyperphosphorylation of tau,
which can cause toxicity downstream of Aβ [4]. To deter-
mine a potential effect of sAPPα on Aβ-induced tau phos-
phorylation primary neuronal cultures were transduced
with neurotropic Sindbis virus to express the 441 amino
acid isoform of human tau selectively in neurons [5].
Furthermore, cultures were treated with 500 nM oligo-
meric Aβ42 or scrambled Aβ42 (Additional file 1). Prepara-
tions of Aβ42 oligomers mainly consist of mono-, tri- and
tetramers (Fig. 1a), which have been shown before to be
cause neuronal dysfunctions [6]. As expected, treatment
with oligomeric Aβ strongly increased tau phosphoryl-
ation at the AD-relevant epitopes AT8 and AT180 (Fig. 1b
and c). The AT8 antibody detects phosphorylation at
Fig. 1 Treatment with sAPPα but not sAPPβ reduces Aβ-induced tau phosphorylation and dendritic spine loss. a Oligomeric Aβ preparations
were characterized by SDS-PAGE followed by silver staining (left panel) or western blot using 6E10 antibody (right panel). Besides monomers,
trimers and tetramers were the main Aβ species obtained by the used oligomerization protocol. b Primary neuronal cultures overexpressing
human 441 tau were treated with 500 nM oligomeric Aβ or scrambled control and 400 ng/ml sAPPα or sAPPβ. AT8 and AT180 phosphorylation
was detected in cell lysates. c Quantification of western blots. Aβ oligomers increased AT8 and AT180 phosphorylation of tau which was
prevented by 400 ng/ml sAPPα but not sAPPβ. Statistical comparison between multiple groups was performed using one-way ANOVA with
Tukey’s test for multiple comparisons n = 5 (*, p < 0,05; **, p > 0,01; ***, p < 0.001;). For important non-significant results, the exact p-values are
displayed. d Representative images of CA1 apical dendritic segments of organotypic hippocampal slice cultures expressing eGFP. Slices were
treated with 500 nM oligomeric Aβ or scrambled control and 400 ng/ml sAPPα or sAPPβ. scale bar = 5 μm e Analysis of dendritic spine density
displayed as spine counts per μm dendrite. Spine density was strongly reduced by Aβ treatment. sAPPα but not sAPPβ diminished dendritic
spine loss caused by Aβ. Statistical comparison between multiple groups was performed using one-way ANOVA with Tukey’s test for multiple
comparisons n = 7–11, Hippocampal slices were prepared from at least 3 different mice per condition. (**, p > 0,01; ***, p < 0.001;). For important
non-significant results, the exact p-values are displayed. Scr. Aβ: scrambled Aβ; AβO: oligomeric Aβ
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Ser202/Thr205, AT180 binds specifically to phosphory-
lated Thr231. Both epitopes are target of the main tau kin-
ase, glycogen synthase kinase 3 beta (GSK-3β) [7].
Co-treatment of cultures with 400 ng/ml recombinant
sAPPα strongly reduced Aβ-induced tau phosphorylation.
In contrast, treatment with sAPPβ had no effect on tau
phosphorylation in the presence of Aβ (Fig. 1b and c).
In addition, we analyzed whether sAPPα and sAPPβ can
modulate dendritic spine densities, as synapse loss strongly
correlates with the degree of dementia in AD. To this end,
we used organotypic slice cultures which were transduced
with Sindbis virus to express enhanced GFP (EGFP). This
method has been described before and allows morpho-
logical analysis of neuronal connectivity in slices [5, 6]. As
previous studies showed that the expression of human tau
in this system does not affect dendritic spine number or
morphology, analysis of spines was performed in the ab-
sence of tau expression for this study [5, 8]. Images of den-
dritic segments in CA1 stratum radiatum were analyzed
for dendritic spine density (Fig. 1d). CA1 stratum radiatum
apical dendrites were chosen as they allow reliable imaging
and evaluation due to the presence of long and straight
dendritic segments. Further, Aβ affects different hippocam-
pal regions, such as CA1 and CA3, to a similar extent [5].
We and others have shown that Aβ reduces the density of
postsynaptic spines and alters their morphology in slice cul-
tures (reviewed in [9]). Accordingly, treatment of slices with
oligomeric Aβ but not scrambled Aβ strongly reduced den-
dritic spine numbers (Fig. 1e). We then determined if
sAPPα or sAPPβ may prevent spine loss. The presence of
400 ng/ml sAPPα completely abolished Aβ-induced spine
loss while sAPPβ-treated slices still displayed a significant
spine reduction (Fig. 1e). To the best of our knowledge, this
is the first report of a protective mechanism of sAPPα for
Aβ-induced dendritic spine loss.
The CSF levels of sAPP in human patients reported in
the literature strongly vary among different studies ranging
from approx. 0,55 ng/ml and 0,25 ng/ml to 1800 ng/ml
and 1600 ng/ml for sAPPα and sAPPβ, respectively [3, 10].
Also, the ratios between sAPPα and sAPPβ vary. For our
analyses we used equimolar levels of sAPPα and sAPPβ at
concentrations within the range described in the literature.
It is important to note that both, sAPPα and sAPPβ alone,
neither affect tau phosphorylation nor dendritic spine
numbers. Thus, the effect of sAPPα represents a specific
protective mechanism against Aβ-induced neuronal dys-
functions rather than a general neurotrophic effect.
sAPPα reduced Aβ-induced tau phosphorylation by in-
creasing the expression of the Aβ-binding protein trans-
thyretin (TTR) [11]. However, the Aβ concentrations used
in that study were very high (50 μM) and no comparison
with sAPPβ was performed. Since we used sAPPβ as con-
trol we can clearly show that the protective property of
sAPPα lies within the C-terminal part of the peptide.
Another study suggested that sAPPα reduces tau phos-
phorylation by GSK-3β inhibition [12]. However, we did
not observe a reduction in tau phosphorylation by treat-
ment with sAPPα in the absence of Aβ oligomers. This
implies that either sAPPα does not inhibit GSK-3β in our
model or that this inhibition only becomes noticeable after
an activation of GSK-3β by Aβ. Thus, it may be interesting
to investigate the potential protective mechanism in our
model in a future study in more detail.
Increasing sAPPα levels by activating α-secretase,
specifically ADAM10, is of therapeutic potential for the
treatment of neurodegenerative conditions including
AD. Accordingly, mild overexpression of ADAM10 pre-
vented amyloid plaque formation and hippocampal de-
fects in transgenic AD mice [13]. However, ADAM10 is
a widely distributed transmembrane protease and in-
volved in shedding many different substrates. Clinical
studies are required to determine whether therapeutic
benefits of α-secretase activation would outweigh po-
tential side effects (reviewed in [14]).
Another current strategy is the pharmacological reduc-
tion of Aβ production by inhibition of γ-secretase using
γ-secretase inhibitors or modulators (GSIs, GSMs).
Recently, it was shown that inhibition of γ-secretase
activity activated a feedback loop leading to increased
α-secretase processing and accelerated release of sAPPα
[15]. Thus, GSIs may act via a dual protective mechan-
ism, reduction of neurotoxic Aβ and elevation of neuro-
protective sAPPα levels.
Taken together, restoration of sAPPα by increasing
non-amyloidogenic processing can reduce Aβ pathology
and therefore represents a valid therapeutic approach
for AD (Additional file 1).
Additional file
Additional file 1: Soluble APPα but not soluble APPβ protects against
Aβ oligomer-induced dendritic spine loss and increased Tau
phosphorylation. (PDF 143 kb)
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